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Abstract
Background: Funding of orphan medicinal products (OMPs) is an increasing challenge in the European Union (EU).
Objectives: To identify the different methods for public funding of OMPs in order to map the availability for rare
disease patients, as well as to compare the public expenditures on OMPs in 8 EU member states.
Methods: Information on the reimbursement status of 83 OMPs was collected in 8 countries by distinguishing
standard and special reimbursements. In two consecutive years, the total public expenditures on OMPs were
calculated by using annual EUR exchange rates. Annual total public expenditures were calculated per capita, and as
a proportion of GDP, total public pharmaceutical and healthcare budgets. Differences between countries were
compared by calculating the deviations from the average spending of countries.
Results: In 2015 29.4–92.8% of the 83 OMPs were available with any kind of public reimbursement in participant
countries including special reimbursement on an individual basis. In Austria, Belgium and France more OMPs were
accessible for patients with public reimbursement than in Bulgaria, Czech Republic, Hungary and Poland. Standard
reimbursement through retail pharmacies and/or hospitals was applied from 0 to 41% of OMPs. The average annual
total public expenditure ranged between 1.4–23.5 €/capita in 2013 and 2014. Higher income countries spent more
OMPs in absolute terms. Participant countries spent 0.018–0.066% of their GDPs on funding OMPs. Average expenditures
on OMPs were ranged between 2.25–6.51% of the public pharmaceutical budget, and 0.44–0.96% of public healthcare
expenditures.
Conclusions: Standard and special reimbursement techniques play different roles in participant countries. The number
of accessible OMPs indicated an equity gap between Eastern and Western Europe. The spending on OMPs as a
proportion of GDP, public pharmaceutical and healthcare expenditure was not higher in lower income countries, which
indicates substantial differences in patient access to OMPs in favour of higher-income countries. Equity in access for
patients with rare diseases is an important policy objective in each member state of the EU; however, equity in access
should be harmonized at the European level.
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Background
Prior to public reimbursement of pharmaceuticals and
medical devices, cost-effectiveness and budget impact
are increasingly applied evaluation criteria alongside
other conditions. Pharmaceutical manufacturers tend to
increase prices of truly innovative new medicines. React-
ing to the increasing health expenditures more and more
third-party payers tend to rationalize their expenditures
by implementing cost-effectiveness criterion. There is
significant tension between manufacturers and payers in
judging the economically justifiable price and this ten-
sion is even more expressive in case of orphan medicinal
products (OMPs) for patients with rare diseases [1, 2].
A developed and morally matured society should judge
the value of therapeutic improvements without taking into
account the rarity of diseases or the opportunity cost of
public spending on new medicines. Objective decision-
making for public reimbursement has to be based on clin-
ical, economic and social criteria, considering the appro-
priateness and uncertainty of evidence [3–7].
Internationally accepted definitions for rare diseases
(RDs) and for OMPs have not been harmonised yet, but
based on the prevalence of diseases different approaches
tend to be quite similar. According to the current defin-
ition of the European Union (EU), the RDs are mostly
inherited life-threatening or chronically debilitating dis-
eases, which affect fewer than 5 out of 10,000 people.
Approximately, 5–8000 RDs and ailments have been di-
agnosed by the medical science [8].
OMPs are indicated for the diagnosis, treatment or
prevention of life-threatening or very serious conditions
of patients with RDs [9]. The purpose of the legislation
was to determine the qualitative criteria of orphan desig-
nation. Furthermore, the Regulation (EC) No. 141/2000
describes the incentives for research, development, and
marketing authorization of medicines/methods intended
for diagnostics, treatment or prevention of RDs [10].
European (or other international) inventories for OMPs
are available on the European Medicines Agency (EMA)
website and official European public assessment reports
(EPAR) [11]. Orphanet is a reference portal for informa-
tion on RDs and OMPs for all audiences. On this web-
site, the orphan designations, as well as the OMPs
authorized by different procedures from various coun-
tries (i.e. EU, Japan, and USA) are listed with related and
relevant information [12].
Usually, the prices of OMPs are significantly higher
than pharmaceutical prices in common diseases. Health
economic evaluation of OMPs is complicated due to dif-
ficulties in selecting policy relevant comparators, wide
confidence intervals of efficacy parameters and serious
adverse events, the lack of hard clinical endpoints in
clinical trials and uncertainty in patient numbers and re-
source utilisation and treatment costs per patient. It is
difficult to measure the efficacy and cost-effectiveness of
OMPs; however, several proposals address this challenge
[13–15]. From another point of view, the willingness to
pay for one unit of health gain might be different for
technologies in RDs; therefore, implementation of trans-
parent criteria for pricing and reimbursement is a big
challenge [16–18].
In almost all EU countries, regulators, payers and
healthcare providers should make additional efforts to
improve the accessibility of patients with RDs to OMPs
by special policy interventions and agreements [19, 20].
However, unaffordable prices and increasing expenditure
on OMPs challenge the sustainability of healthcare fund-
ing in all countries [21].
Previous studies concluded that external price referen-
cing system prevented lower-income Central and East-
ern European (CEE) countries from implementing value
based pharmaceutical prices [22]. While the public
healthcare budgets in lower-income countries are signifi-
cantly lower, relatively higher OM prices induce greater
burden to reimburse these medicines in CEE [23, 24].
Our objective was to draw a map on the economic
burden of 83 medicines with designated OM status in
2015 by EMA in 8 EU countries with different economic
status and population size, including Austria, Belgium,
Bulgaria, Czech Republic, France, Hungary, Poland and
Slovenia. We investigated two aspects of patient access
in countries with different economic status, the availabil-
ity of OMPs with public reimbursement in 2015, and the
public expenditure on OMPs in 2013 and 2014. We ana-
lysed whether public reimbursement is an increased
challenge for lower-income countries.
Methods
We found 83 medicines based on the list OMPs pub-
lished at the Orphanet website and validated the list
based on the pharmaceutical database of EMA [25, 26].
Competent authorities or institutes in the 8 participant
countries were contacted to provide reimbursement sta-
tus of these OMPs with specific details on the applied
reimbursement technique in 2015. We intended to col-
lect data from 8 countries with various population size
and different geographical and economic status across
the EU.
We evaluated reimbursement status in five categories,
including (1) standard reimbursement through both retail
pharmacies and hospitals; (2) standard reimbursement
through retail pharmacies; (3) standard reimbursement in
hospitals only; (4) special patient level reimbursement that
is not automated based on patient eligibility but on indi-
vidual requests; and (5) no public reimbursement.
The qualitative (reimbursement techniques) and quan-
titative data (total public expenditures - pharmaceutical
and healthcare budgets) were provided by the national
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public administration bodies summarized in Table 1.
Demographic and economic data (size of population, ex-
change rates, GDP) was obtained from the Eurostat web-
site as the footnotes of the tables show. Austrian
demographic data was not available in the Eurostat data-
base, the source was the OECD website.
We also collected country level data on public OM
spending in 2013 and 2014. Annual average total public
expenditures in 2013–14 were calculated per capita, and
as a proportion of GDP, total public pharmaceutical and
healthcare budgets. We converted spending to Euros by
applying the annual currency exchange rates based on
Eurostat data.
We compared public expenditure on ten specific
OMPs per 100.000 inhabitants in 2013 and 2014. We
intended to select a representative sample of OMPs
based on different attributes as field of the indication,
existing therapeutic alternative, relative effectiveness
(potentially curative/non-curative treatment), rarity (or-
phan/ ultra-orphan status) and cost commitment, as the
Table 2 shows. A heterogeneous group of OMPs was
collected, including idursulfase for mucopolysaccharido-
sis type II., rifunamide for Lennox–Gastaut syndrome,
romiplostim for idiopathic thrombocytopenic purpura,
trabectedin for sarcomas and ovarian neoplasms, nelara-
bine for special types of leukaemia or lymphoma, silden-
afil for pulmonary hypertension, alglucosidase alfa for
glycogen storage disease type II, icatibant for inadequate
or non-functioning C1-Inhibitor protein and sapropterin
for phenylketonurias, and eculizumab for paroxysmal
nocturnal haemoglobinuria or for atypical haemolytic
uremic syndrome.
Results
In 2015, 29.4–92.8% of the 83 OMPs were available with
any kind of public reimbursement in participant coun-
tries including special reimbursement on individual basis
(see Fig. 1). The standard reimbursement listing was
ranged from 0 to 41%.
Within the standard reimbursement techniques we
distinguished reimbursement for outpatient care through
retail pharmacies or inpatient care through hospitals.
Patients in Austria and France had over 90% access
rate to OMPs, in Bulgaria and Poland patients had ac-
cess to less than 30% of the 83 OMPs. The details of
public reimbursement status of OMPs in 2015 are pre-
sented in the Additional file 1.
Data on public expenditure of OMPs was not access-
ible in France. In the 7 participant countries total public
expenditures on OMPs were increased from 1.13–21.95
€/capita (mean: 7.36 €/capita) in 2013 to 1.69–25.04
€/capita (mean: 8.66 €/capita) in 2014. The average
spending per capita in 2013–14 was ranged be-
tween1.41–23.50 € (mean: 8.63 €/capita). The absolute
spending per capita showed 16.7 fold differences be-
tween countries with the highest and lowest spending.
However, it should be noted that no data were available
on hospital expenditure of OMPs from Austria and
Bulgaria. Results are summarized in Table 3.
As the Table 4 shows, average expenditures on OMPs
ranged between 2.25–6.51% of the public pharmaceutical
budget, and 0.44–0.96% of public healthcare expendi-
tures in 2013–14. No data was available for Austria and
Bulgaria.
Data on the public expenditure of the 10 selected
OMPs in different therapeutic areas were not available
in France and Austria. Compared to the average spend-
ing of participant countries, Belgium and Slovenia had
significantly higher spending, whilst spending in Bulgaria
and Poland was far below the average. (See Table 5.)
We made a similar calculation for those three OMPs
that were accessible for patients with public reimburse-
ment in the countries in 2013–14 (see Table 6). Accord-
ing to the Hungarian regulation, financial data of some
OMPs among the indicators were allowed to published
only as summarized amounts, therefore we were not
able to separate the annual total expenditures of these
OMPs, thus we had to ignore the Hungarian data.
Based on the ratio of country specific spending com-
pared to the average spending of participant countries
(see Table 5 and Table 6) similar tendency can be ob-
served; wealthier countries spend more per capita on
ODs than lower-income countries.
Discussion
According to our data, accessibility to OMPs is associ-
ated with the economic status of the member state (MS)
Table 1 The sources of the data per Member State
Austria Federation of Austrian Social Insurance Institutions
(Hauptverband der österreichischen Sozialversicherungsträger)
Belgium National Institute for Health and Disability Insurance of
Belgium
(Institut National d’Assurance Maladie-Invalidité /
Rijksinstituut voor ziekte-en invaliditeitsverzekering,
INAMI / RIZIV)
Bulgaria National Health Insurance Fund (NHIF)
National Council on Prices and Reimbursement of
Medicinal Products (NCPR)
Czech
Republic
State Institute for Drug Control
(Státní ústav pro kontrolu léčiv, SUKL)
France French National Authority for Health
(Haute Autorité de Sante, HAS)
Hungary National Health Insurance Fund Administration
of Hungary
(Országos Egészségbiztosítási Pénztár, OEP)
Poland National Health Fund (Narodowy Fundusz Zdrowia),
Ministry of Health (Ministerstwo Zdrowia)
Slovenia Health Insurance Institute of Slovenia
(Zavod za zdravstveno zavarovanje Slovenije, ZZZS)
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[22, 27]. In Austria, Belgium and France more OMPs
were accessible for patients with public reimbursement
than in Bulgaria, Czech Republic, Hungary, and Poland
indicating an equity gap between Eastern and Western
Europe. Slovenia was in between Western-European and
CEE countries.
The reimbursement categories of OMPs are related to
different decision criteria. Although market access cri-
teria of OMPs with standard reimbursement listing
through retail pharmacies may not be as strong as
criteria for pharmaceuticals in common diseases, OMPs
with such reimbursement status at least go through a
centralised evaluation procedure and price negotiation
in the MSs. Evaluation criteria and price negotiation for
OMPs with standard reimbursement in hospitals only
may be less sophisticated in some countries compared
to OMPs on the outpatient reimbursement list.
In Belgium and France other than standard reimburse-
ment techniques do not exist. Special individual reim-
bursement might be available only for children (<
Table 2 The attributes for selection of 10 Orphan Medicinal Products
Field of the indicationa Other
therapeutic
alternative(s)?a
Clinical/Relative Effectiveness
(potentially curative/non-
curative treatment)a
Rarity (orphan/ ultra-
orphan status)a
Cost commitmentb
Alglucosidase
alfa
Glycogen storage disease type II No Incremental (non-curative) UO Medium
Eculizumab Paroxysmal nocturnal haemoglobinuria
or for atypical haemolytic uremic syndrome
No Major (non-curative) O High
Icatibant Hereditary angioedema Yes Major (non-curative) O Medium
Idursulfase Mucopolysaccharido-sis type II No Incremental (non-curative) UO High
Nelarabine Special types of leukaemia or lymphoma No Curative O Medium
Rufinamide Lennox–Gastaut syndrome Yes Major (non-curative) O Low
Romiplostim Idiopathic thrombocytopenic purpura No Curative O Medium
Sapropterin Phenylketonuria Yes Major (non-curative) O Low
Sildenafil Pulmonary hypertension No Major (non-curative) O Low
Trabectedin Sarcomas and ovarian neoplasms No Incremental (non-curative) O High
Abbreviations: O Orphan Medicinal Product, UO Ultra-orphan medicinal product
Sources: a The European public assessment reports (EPAR) for human medicines published by the European Medicines Agency
(EMA) http://www.ema.europa.eu/ema/
bNational Health Insurance Fund Administration of Hungary (Országos Egészségbiztosítási Pénztár, OEP)
Fig. 1 Reimbursement Status of Orphan Medicines in 8 EU Member States in 2015
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18 years) in Bulgaria. However, the application of special
reimbursement for individual patients cannot be associ-
ated with the economic status of participant countries.
There are substantial differences in the total public ex-
penditure on OMPs per capita in participant countries.
The absolute spending is clearly associated with the eco-
nomic status of countries. If we assume a narrow price
corridor across countries due to the widely used external
price referencing system, confidential discounts, unequal
spending translates to inequity in access to OMPs. Inter-
estingly, the spending on OMPs as a proportion of GDP,
public pharmaceutical and healthcare expenditure was
not higher in lower-income countries compared to those
with higher-income, which also indicates substantial dif-
ferences in patient access to OMPs in favour of higher-
income countries. However, we must emphasize that
utilisation of OMPs highly depends on many other fac-
tors, including the prevalence of RDs or the availability
of diagnostic facilities.
European collaboration is a crucial need to improve
equal access to OMPs across the European Union. Re-
garding the registration and health technology assess-
ment step, existing networks, initiatives and proposals -
such EUnetHTA [28]; EU proposal on HTA [29] - have
a predominant role to exchange and collect information,
and summarize knowledge in order to create one thera-
peutic, scientific compilation report to support the cen-
tralized procedure of the marketing authorization; and
to facilitate the decision-making process with semi-
qualitative transparent value matrix as the MOCA pro-
ject recommended or with the framework provided by
the multi-criteria decision analysis model [30].
Table 3 The Total Public Expenditure on OMPs in Euro per Capita in 7 EU Countries in 2013 and 2014
Austrial Belgium Bulgariam Czech
Republicn
Hungary Poland Slovenia
2013
Total public expenditure on OMPs in
local currency
98,600,000
€a
245,000,000
€b
16,201,220
BGNc
1,100,000,000
CZKd
9,577,605,323 HUFe 212,725,536 PLNf 16,893,308 €g
Eurostat exchange rate - annual
data (/1 €)
1.96 BGNh 25.98 CZKh 296.87 HUFh 4.20 PLNh
Total public expenditure on OMPs
in €
98,600,000 245,000,000 8266,000 42,340,000 32,262,000 50,649,000 16,893,000
Size of population 8,500,000j 11,161,642i 7,284,552i 10,516,125i 9,908,798i 38,062,535i 2,058,821i
Total public expenditure on OMPs
in €/capita
11.60 21.95 1.13 4.03 3.26 1.33 8.21
2014
Total public expenditure on OMPs
in local currency
109,800,000
€a
280,000,000
€b
23,967,183
BGNc
1,400,000,000
CZKo
12,501,994,171 HUFe 348,368,792PLNf 19,853,716 €g
Eurostat exchange rate - annual
data (/1 €)
1.96 BGNh 27.54 CZKh 308.71 HUFh 4.18 PLNh
Total public expenditure on OMPs
in €
109,800,000 280,000,000 12,228,000 50,835,000 40,496,000 83,342,000 19,854,000
Size of population 8,500,000k 11,180,840i 7,245,677i 10,512,419i 9,877,365i 38,017,856i i2,061,085
Total public expenditure on OMPs
in €/capita
12.92 25.04 1.69 4.84 4.10 2.19 9.63
Average of total expenditure on
OMP in €/capita in 2013 and 2014
12.26 23.50 1.41 4.43 3.68 1.76 8.92
Sources: a Federation of Austrian Social Insurance Institutions (Hauptverband der österreichischen Sozialversicherungsträger)
bNational Institute for Health and Disability Insurance of Belgium (Institut National d'Assurance Maladie-Invalidité / Rijksinstituut voor ziekte-en
invaliditeitsverzekering, INAMI / RIZIV)
cNational Health Insurance Fund of Bulgaria, National Council on Prices and Reimbursement of Medicinal Products
dState Institute for Drug Control (Státní ústav pro kontrolu léčiv, SUKL)
e National Health Insurance Fund Administration of Hungary (Országos Egészségbiztosítási Pénztár, OEP)
fNational Health Fund (Narodowy Fundusz Zdrowia), Ministry of Health (Ministerstwo Zdrowia)
g Health Insurance Institute of Slovenia (Zavod za zdravstveno zavarovanje Slovenije, ZZZS)
hhttp://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=ert_bil_eur_a&lang=en
ihttp://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo_gind&lang=en
jAustrian data was not available on Eurostat database, the source: https://data.oecd.org/pop/population.htm
kAustrian data was not available on Eurostat or OECD database, the calculated number was taken from the previous year
lOrphan drug expenditure in hospitals not included
mThese data was based on 10 OMs reimbursed by National Health Insurance Fund
nAdditional drugs were identified which held orphan designation until 2013/14 with significant costs (Glivec, Ilaris, Ventavis)
oData was not available at time of data request; this number assumes same total expenditure on public healthcare as in year 2013
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Table 4 Total Public Expenditure on OMPs in 2013 and 2014 compared to GDP, Total Pharmaceutical and Healthcare Budget
Austriac Belgium Bulgaria Czech
Republic
Hungary Poland Slovenia
2013
Total public expenditures on OMPs (thousand €) 98,600a 245,000a 8266a 42,340a 32,262a 50,649a 16,893a
Total GDP (thousand €) 322,539,200b 391,712,000b 42,011,500b 157,741,600b 101,483,300b 394,721,100b 35,917,100b
Total public expenditures on OMPs in
proportion of GDP (%)
0.03% 0.06% 0.02% 0.03% 0.03% 0.01% 0.05%
% of total pharmaceutical expenditures 3.74% e 6.18% f 3.07% g 2.00% h 3.42% i 1.95% j 4.65% k
% of total healthcare expenditures NA 0.91% f NA 0.4% h 0.53% i 0.34% j 0.74% k
Total pharmaceutical expenditures (thousand €)
(calculated)
2,636,364 3,964,401 269,248 2,117,013 943,332 2,597,381 363,297
Total healthcare expenditures (thousand €)
(calculated)
NA 26,923,077 NA 10,585,065 6,087,161 14,896,746 2,282,879
2014
Total public expenditures on OMPs (thousand €)
(Growth compared to 2013, %)
109,800
(+ 11.4%)a
280,000
(+ 14.3%)a
12,228
(+ 47.9%)a
50,835
(+ 20.1%)a
40,498
(+ 25.5%)a
83,341
(+ 64.5%)a
19,854
(+ 17.5%)a
Total GDP (thousand €) 330,417,600b 400,805,000b 42,762,200b 166,964,100b 104,953,300b 410,989,700b 37,332,400b
Total public expenditures on OMPs in
proportion of GDP (%)
0.03% 0.07% 0.03% 0.03% 0.04% 0.02% 0.05%
% of total pharmaceutical expenditures 3.94%e 6.84% f 4.15% g 2.50% h 4.25% i 3.2% j 5.47% k
% of total healthcare expenditures NA 1.01% f NA 0.60% h 0.66% i 0.54% j 0.84% k
Total pharmaceutical expenditures (thousand €)
(calculated)
2,786,802 4,093,567 294,654 2,033,406 952,883 2,604,432 362,956
Total healthcare expenditures (thousand €)
(calculated)
NA 27,722,772 NA 8,472,525 6,135,990 15,433,670 2,363,538
Total public expenditures on OMPs in proportion
of GDP (%) in 2013
0.03% 0.06% 0.02% 0.03% 0.03% 0.01% 0.05%
Total public expenditures on OMPs in proportion
of GDP (%) in 2014
0.03% 0.07% 0.03% 0.03% 0.04% 0.02% 0.05%
Average 0.03% 0.07% 0.02% 0.03% 0.04% 0.02% 0.05%
Total public expenditure on OMPs as a proportion
of total public pharmaceutical expenditures in 2013
3.74% 6.18% 3.07% 2.00% 3.42% 1.95% 4.65%
Total public expenditure on OMPs as a proportion
of total public pharmaceutical expenditures in 2014
3.94% 6.84% 4.15% 2.50%d 4.25% 3.20% 5.47%
Average 3.84% 6.51% 3.61% 2.25% 3.84% 2.58% 5.06%
Total public expenditure on OMPs as a proportion
of total public healthcare expenditures in 2013
NA 0.91% NA 0.40% 0.53% 0.34% 0.74%
Total public expenditure on OMPs as a proportion
of total public healthcare expenditures in 2014
NA 1.01% NA 0.60%d 0.66% 0.54% 0.84%
Average NA 0.96% NA 0.50% 0.60% 0.44% 0.79%
Sources: a Data was given from Table 1
bhttp://ec.europa.eu/eurostat/tgm/refreshTableAction.do?tab=table&plugin=1&pcode=tec00001&language=en
cOrphan drug expenditure in hospitals not included
dData was not available at time of data request. this number assumes same total expenditure on public healthcare as in year 2013
eFederation of Austrian Social Insurance Institutions (Hauptverband der österreichischen Sozialversicherungsträger)
fNational Institute for Health and Disability Insurance of Belgium (Institut National d'Assurance Maladie-Invalidité / Rijksinstituut voor ziekte-en
invaliditeitsverzekering, INAMI / RIZIV)
gNational Health Insurance Fund of Bulgaria, National Council on Prices and Reimbursement of Medicinal Products
hState Institute for Drug Control (Státní ústav pro kontrolu léčiv, SUKL)
iNational Health Insurance Fund Administration of Hungary (Országos Egészségbiztosítási Pénztár, OEP)
jNational Health Fund (Narodowy Fundusz Zdrowia), Ministry of Health (Ministerstwo Zdrowia)
kHealth Insurance Institute of Slovenia (Zavod za zdravstveno zavarovanje Slovenije, ZZZS)
Szegedi et al. Orphanet Journal of Rare Diseases          (2018) 13:184 Page 6 of 8
It should maintain bilateral connections for the na-
tional HTA authorities - to participate in the informa-
tion summarization and to provide a well-informed basis
for the national assessment procedure [31, 32].
The central regulatory body should require and pro-
vide the compilation report accessible at the time of
marketing authorization and towards, as well as the per-
manent mapping and announcement of unmet needs of
MSs.
The generalizability of the findings may be limited due
to several reasons. First of all, it should be emphasized
that the orphan status of medicines is flexible and can
change over time. We have not evaluated the availability
of other funding channels, including early access pro-
grams, donations, and compassionate use. Finally, we
did not have access to all of the data in every participant
country.
Conclusions
European policymakers pay special attention to posi-
tively discriminate patients with rare diseases. There are
international policy tools to facilitate the research and
development of orphan medicinal products, and payers
in some countries may apply special criteria to approve
the reimbursement of OMPs. Consequently we can state
that equity in OM access for patients with rare diseases
is an important policy objective in each member state of
the European Union. However, our study indicates ser-
ious inequity in access across EU member states, which
requires additional research and consequently harmo-
nised policy actions at the European level.
Our research could not prove that the public funding of
OMPs would be a greater burden to the lower-income
countries, mainly because these countries manage the sus-
tainability of public healthcare funding by limiting patient
access to high cost therapies.
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